Biopharmaceutical / Advanced Cell Therapy / Regenerative Medicine
Strategic Profile
Vericel operates by turning a patient's own healthy cells into personalized, living therapies to repair damaged tissue, positioning itself as a specialized leader in regenerative medicine with 2025 full-year total revenue guidance projected between $272 million and $276 million. The company demonstrates strong operational fundamentals with a gross margin of 73.5%, a robust cash position of approximately $185 million, and carries absolutely no debt, minimizing financial risk and supporting long-term strategic investments.
Cyborg Score Rationale
The company's strong gross margin of 73.5% and record Q3 2025 revenue of $67.5 million demonstrate operational excellence. Record operating cash flow of $22.1 million in Q3 2025 and a robust balance sheet with $185 million in cash and zero debt show excellent financial health. However, the company operates in a specialized niche market with regulatory and competitive pressures requiring sustained innovation.
Top Insights
Q3 2025 revenue reached a record $67.5 million with 73.5% gross margins, driven by MACI cartilage repair and Epicel burn care products.
Zero debt combined with $185 million in cash positions the company for sustainable long-term investment and strategic flexibility.
Recent FDA approval of MACI Arthro enables less-invasive arthroscopic delivery for knee cartilage defects up to 4 cm², expanding addressable market.
Management guidance of $272-$276 million full-year 2025 revenue with MACI contributing $237.5-$239.5 million reflects strong market traction.
Named Competitors
Cartilage Repair Products — Traditional orthopedic repair devices and matrices for cartilage defects
Burn Care Solutions — Various traditional and advanced burn care treatment modalities
Cell Therapy Competitors — Early-stage cell and gene therapy platforms for tissue repair
Recent Developments
(February 2026) 10-K filing showing market capitalization of approximately $2.1 billion reflects investor confidence in innovative therapies.
(2025) Record Q3 revenue of $67.5 million achieved with record operating cash flow of $22.1 million in Q3 2025.
(2025) FDA approval for MACI Arthro enabling arthroscopic delivery of knee cartilage repair with smaller incisions.
(2025) Pediatric FDA approval for NexoBrid for eschar removal in deep partial and full-thickness thermal burns.
Open the full interactive Vericel Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.